Who is sponsoring NCT05601505?

NCT05601505 is sponsored by Peking Union Medical College Hospital.

What drugs are being tested in NCT05601505?

Interventions in NCT05601505: circulating tumor DNA.

What condition does NCT05601505 study?

NCT05601505 studies Locally Advanced Rectal Carcinoma, Circulating Tumor DNA.

Is NCT05601505 still recruiting?

NCT05601505 is currently recruiting now. Last updated 24 December 2024.

Last reviewed 2024-12-24 · How we verify

NCT05601505: CINTS-R

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Circulating Tumor DNA-guided Neoadjuvant Treatment Strategy for Locally Advanced Rectal Cancer

Recruiting now Phase 2 Last updated 24 December 2024

What this trial tests

Phase 2 trial testing circulating tumor DNA in Locally Advanced Rectal Carcinoma in 470 participants. Currently enrolling.

Timeline

3 February 2023

Primary endpoint
31 October 2025

1 November 2026

Quick facts

Lead sponsor	Peking Union Medical College Hospital
Phase	Phase 2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	470
Start date	3 February 2023
Primary completion	31 October 2025
Estimated completion	1 November 2026
Sites	1 location across China

Drugs / interventions tested

circulating tumor DNA

Conditions studied

Locally Advanced Rectal Carcinoma — all drugs for Locally Advanced Rectal Carcinoma →
Circulating Tumor DNA — all drugs for Circulating Tumor DNA →

Sponsor

Peking Union Medical College Hospital

Who can join

Adults 18 to 75, any sex, with Locally Advanced Rectal Carcinoma or Circulating Tumor DNA. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Rectal cancer still remains one of the most popular tumors, however, distance metastasis still remains as high as 30% and the long-term survival outcomes are still unsatisfying. The recent conception of total neoadjuvant therapy and immune therapy is becoming popular and the oncologic effects are encouraging, especially in terms of circulating tumor DNA (ctDNA), the prognostic value of ctDNA has been demonstrated by our prior study. This study will carry out accurate ctDNA-guided neoadjuvant therapy on the basis of previous studies of the research group, and give appropriate treatment plans and treatment intensity to patients with different disease degrees. At the same time, combined with the latest progress in clinical diagnosis and treatment, the potential beneficiaries of immunotherapy were screened scientifically, and the combined immunotherapy was implemented accordingly.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

The Position of Circulating Tumor DNA in the Clinical Management of Colorectal Cancer.
de Abreu AR, Op de Beeck K, Laurent-Puig P, Taly V, et al · · 2023 · cited 14× · PMID 36831626 · DOI 10.3390/cancers15041284
Circulating tumor DNA for MRD detection in colorectal cancer: recent advances and clinical implications.
Ma D, Gao X, Wang L, Yin H, et al · · 2025 · cited 8× · PMID 40551262 · DOI 10.1186/s40364-025-00796-w
Assessing circulating tumour DNA (ctDNA) as a prognostic biomarker in locally advanced rectal cancer: a systematic review and meta-analysis.
O'Sullivan NJ, Temperley HC, Kyle ET, Sweeney KJ, et al · · 2024 · cited 8× · PMID 38809315 · DOI 10.1007/s00384-024-04656-1
Circulating tumour DNA in predicting and monitoring survival of patients with locally advanced rectal cancer undergoing multimodal treatment: long-term results from a prospective multicenter study.
Zhou J, Li L, Liu Y, Jia W, et al · · 2025 · cited 6× · PMID 39818166 · DOI 10.1016/j.ebiom.2024.105548
A Review of Circulating Tumor DNA as a Biomarker Guide for Total Neoadjuvant Therapy in Patients with Locally Advanced Rectal Cancer.
Yahya J, Baber M, Nabavizadeh N, Goodyear SM, et al · · 2023 · cited 5× · PMID 36719559 · DOI 10.1007/s12029-022-00906-z
Rationale and design of a multicentre randomised controlled trial on circulating tumour DNA-guided neoadjuvant treatment strategy for locally advanced rectal cancer (CINTS-R).
Zhou J, Zhang X, Liu Q, Li Y, et al · · 2025 · cited 4× · PMID 39894522 · DOI 10.1136/bmjopen-2024-090765
Circulating tumor DNA in colorectal cancer: biology, methods and applications.
Chen H, An Y, Wang C, Zhou J. · · 2025 · cited 2× · PMID 40167831 · DOI 10.1007/s12672-025-02220-z
The Method of Minimal Residual Disease Detection With Circulating Tumor DNA and Its Clinical Applications in Colorectal Cancer.
Liu M, Mu T, Gu J, Xu M, et al · · 2025 · cited 2× · PMID 40033897 · DOI 10.1002/cnr2.70167

Verify or expand the search:

Other trials of circulating tumor DNA

Trials testing the same drug.

NCT06157060 — Prediction of Hepatocellular Carcinoma Recurrence After Curative Treatment by Longitudinal Monitoring MRD Based on ctDNA · recruiting

Other recruiting trials for Locally Advanced Rectal Carcinoma

Currently open trials in the same condition.

NCT07372300 — Modulated Electro-Hyperthermia in Combination With Multimodal Therapy for Locally Advanced Rectal Cancer · Phase 3 · recruiting
NCT07038122 — Reducing the Resection Range After Neoadjuvant Therapy for Locally Advanced Upper Rectal and Rectosigmoid Junction Cance · NA · active not recruiting
NCT06276686 — Exercise for Improving Long-course Chemoradiotherapy Efficacy in People With Locally Advanced Rectal Cancer · EARLY_PHASE1 · recruiting
NCT06312982 — A Series of Neoadjuvant Chemoradiotherapy Combined With Immunotherapy for Locally Advanced Rectal Cancer · Phase 2, PHASE3 · recruiting
NCT05731726 — Serplulimab Combined With CAPEOX + Celecoxib as Neoadjuvant Treatment for Locally Advanced Rectal Cancer · Phase 2 · recruiting

Other Peking Union Medical College Hospital trials

Trials by the same sponsor.

NCT07466251 — PCSK9 Inhibitor for Intracranial Atherosclerosis Related Acute Ischemic Stroke · Phase 4 · not yet recruiting
NCT06743321 — Speech-to-speech Voice-cloning Care (SVCC) to Improve ICU-acquired Anxiety for Critically Ill Patients · NA · not yet recruiting
NCT07590336 — 68Ga-NYM207 PET/CT Imaging in Hepatocellular Carcinoma · Phase 1, PHASE2 · not yet recruiting
NCT07515976 — Mapping of Genomic Structural Variations in Major Birth Defects · not yet recruiting
NCT07386756 — Early Precise Identification and Intervention Strategies for Individuals at High Risk of Prediabetes · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05601505 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Peking Union Medical College Hospital
Last refreshed: 24 December 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05601505.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing